Soluble NKG2D ligands: prevalence, release, and functional impact.
about
Human NKG2D-ligands: cell biology strategies to ensure immune recognitionNatural killer cell cytotoxicity is suppressed by exposure to the human NKG2D ligand MICA*008 that is shed by tumor cells in exosomesWiskott-Aldrich syndrome protein (WASp) and N-WASp are involved in the regulation of NK-cell migration upon NKG2D activationGlycosyl-Phosphatidyl-Inositol (GPI)-Anchors and Metalloproteases: Their Roles in the Regulation of Exosome Composition and NKG2D-Mediated Immune RecognitionCytotoxicity and infiltration of human NK cells in in vivo-like tumor spheroids.MHC class I chain-related protein A and B (MICA and MICB) are predominantly expressed intracellularly in tumour and normal tissue.Antibody-mediated neutralization of soluble MIC significantly enhances CTLA4 blockade therapy.Thermal- and oxidative stress causes enhanced release of NKG2D ligand-bearing immunosuppressive exosomes in leukemia/lymphoma T and B cellsHIV-1 Vpr up-regulates expression of ligands for the activating NKG2D receptor and promotes NK cell-mediated killing.Palmitoylation of MICA, a ligand for NKG2D, mediates its recruitment to membrane microdomains and promotes its shedding.Elevation of soluble major histocompatibility complex class I related chain A protein in malignant and infectious diseases in Chinese patientsExpression, signaling proficiency, and stimulatory function of the NKG2D lymphocyte receptor in human cancer cells.Expression of MICA, MICB and NKG2D in human leukemic myelomonocytic and cervical cancer cells.Soluble ligands for the NKG2D receptor are released during endometriosis and correlate with disease severity.Prostate tumor-derived exosomes down-regulate NKG2D expression on natural killer cells and CD8+ T cells: mechanism of immune evasion.Acquisition of activation receptor ligand by trogocytosis renders NK cells hyporesponsive.Oxidative DNA damage in the prostate may predispose men to a higher risk of prostate cancer.Immune-mediated liver diseases: programmed cell death ligands and circulating apoptotic markers.Human fused NKG2D-IL-15 protein controls xenografted human gastric cancer through the recruitment and activation of NK cells.Natural Killer Group 2D Ligand Depletion Reconstitutes Natural Killer Cell Immunosurveillance of Head and Neck Squamous Cell Carcinoma.Soluble MHC I and soluble MIC molecules: potential therapeutic targets for cancer.Mechanisms of tumor and viral immune escape from natural killer cell-mediated surveillance.Human NK cells in acute myeloid leukaemia patients: analysis of NK cell-activating receptors and their ligands.Generation of soluble NKG2D ligands: proteolytic cleavage, exosome secretion and functional implications.Alternative Splice Transcripts for MHC Class I-like MICA Encode Novel NKG2D Ligands with Agonist or Antagonist Functions.Nonblocking Monoclonal Antibody Targeting Soluble MIC Revamps Endogenous Innate and Adaptive Antitumor Responses and Eliminates Primary and Metastatic Tumors.c-Cbl regulates MICA- but not ULBP2-induced NKG2D down-modulation in human NK cells.DNA damage response and evasion from immunosurveillance in CLL: new options for NK cell-based immunotherapies.The bispecific immunoligand ULBP2-aCEA redirects natural killer cells to tumor cells and reveals potent anti-tumor activity against colon carcinoma.Activation of NK cells and disruption of PD-L1/PD-1 axis: two different ways for lenalidomide to block myeloma progressionAntigen Loss Variants: Catching Hold of Escaping Foes.Shedding of endogenous MHC class I-related chain molecules A and B from different human tumor entities: heterogeneous involvement of the "a disintegrin and metalloproteases" 10 and 17.Rescue of impaired NK cell activity in hodgkin lymphoma with bispecific antibodies in vitro and in patients.Ataxia-telangiectasia mutated kinase-mediated upregulation of NKG2D ligands on leukemia cells by resveratrol results in enhanced natural killer cell susceptibility.Intimate cross-talk between cancer cells and the tumor microenvironment of B-cell lymphomas: The key role of exosomes.Impaired tumor rejection by memory CD8 T cells in mice with NKG2D dysfunction.NKG2D- and T-cell receptor-dependent lysis of malignant glioma cell lines by human γδ T cells: Modulation by temozolomide and A disintegrin and metalloproteases 10 and 17 inhibitorsSoluble MICA is elevated in pancreatic cancer: Results from a population based case-control study.Soluble ligands for NK cell receptors promote evasion of chronic lymphocytic leukemia cells from NK cell anti-tumor activity.Association of MICA Alleles with Autoimmune Thyroid Disease in Korean Children.
P2860
Q21131219-F3D4D018-8F5F-4875-841F-3BC429D52C4EQ24294847-8C157F51-8747-4216-A11D-1D1ECAA6A0BFQ24322081-2272EDE8-FF0C-49DB-90F8-13D9AF71A88FQ28076151-A8208F1C-9A69-4FE3-999E-53206B150ACEQ30648415-0AF1D1D3-B58B-4744-B809-352541B4ECD6Q33639723-1DA0474A-3916-4938-8AAE-DBCA25F9F912Q33699687-F8A3E06F-40D8-45E7-A49D-7C8415471DC6Q33833898-ACEE4700-B7BC-4D6B-B1E0-1EE5652519B8Q34087997-AC432F37-8668-41A3-A263-C6ACAD6B09ADQ34217314-A6AE321C-3627-44A6-BB92-EAB7D68DBDF2Q34488774-A63DA4C1-50F0-4054-9A4D-47EF36E8926CQ34652549-FDA4A4E9-57C3-4AA7-A45F-754219C90019Q34855104-E79BDA69-B2A7-4EE8-8EDA-AF73843CA813Q35181683-71647D32-D0FB-4E4B-B8D1-259B8DAB930FQ35287627-0A408F6F-60D8-46C9-AA9F-94EDEAA0706FQ35541252-0A60CD37-C7C4-4439-B856-1368AA308078Q37109463-1D29357B-7C24-4D16-B40D-6CEEAEE48512Q37418054-AC9BB373-0606-4FB5-99A6-B51DC2D1FDADQ37714638-5E9B35E9-C6F4-45B8-9522-BE11936F865AQ37743484-FEBD16E2-4CF1-47A4-9DB8-A086EE20228DQ37828518-D2FBE5EE-DEDA-4265-A0F9-4CCA716069FDQ37876089-2D5B0589-A053-40C3-83AA-4D4767DE505EQ37885284-D39516DA-62D9-4A98-80E7-AE5B257D0958Q38107250-C04FACEC-356B-458E-8B1D-904FD2DB3385Q38762336-9D03E629-5A6C-4685-BA60-8331A3764419Q38860610-1E399A29-7D15-4AA1-9493-2AC2BF359F46Q38993228-41180BCA-394D-43BF-96A2-60160641111FQ39037081-79BDCE57-07CE-4653-BC81-712FDA673F31Q39062237-7A7EAF5E-1D0D-4E31-AEAD-AFDF261B7BB4Q39136762-48A34564-EA6B-4BAC-8757-DF3B3318AB69Q39175440-18629A62-49FB-4859-834E-689A7B930364Q39176227-247BA971-5113-4780-AA72-77E97F4AD4D8Q39185522-77E80623-EE56-4609-AFEE-61206725DAA0Q39187764-297721B6-03C9-4243-9832-3FBF87209E03Q39376074-95D14C16-3C15-40AC-9459-442C0DC8CC33Q39537390-41C13CFD-EC5F-4D4E-BCA2-C81F7D7049E7Q39798606-A0F3FD3B-9EE0-4400-9949-B806CFE8B5C2Q40215861-98DFE192-66BF-4621-8971-BE515C5BF5DEQ40372471-C337CDFE-DF1F-4DB5-B7B4-B65F1AB48C7FQ41732574-A200510E-2032-4ED2-995F-F576BCDB989A
P2860
Soluble NKG2D ligands: prevalence, release, and functional impact.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Soluble NKG2D ligands: prevalence, release, and functional impact.
@en
Soluble NKG2D ligands: prevalence, release, and functional impact.
@nl
type
label
Soluble NKG2D ligands: prevalence, release, and functional impact.
@en
Soluble NKG2D ligands: prevalence, release, and functional impact.
@nl
prefLabel
Soluble NKG2D ligands: prevalence, release, and functional impact.
@en
Soluble NKG2D ligands: prevalence, release, and functional impact.
@nl
P356
P1476
Soluble NKG2D ligands: prevalence, release, and functional impact
@en
P2093
Helmut Rainer Salih
Stefan Holdenrieder
P304
P356
10.2741/2939
P577
2008-05-01T00:00:00Z